ClinicalTrials.gg
RecruitingNCT02317328Updated Nov 5, 2026

Adaptive Optics Retinal Imaging

An observational study in Eye Diseases and Healthy Volunteers, sponsored by National Eye Institute (NEI). Recruiting at 1 site in United States. Open to participants aged 12 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by National Eye Institute (NEI) · Observational

How we know

From the registry’s dates

  • Started Feb 2015; still recruiting 11 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
1,000
Ages
12 Years to 120 Years
Sex
All
01

Study summary

Background:

- By the time diseases of the retina are detected, serious damage has often already been done. Researchers want to find better ways of viewing the retina. One way called adaptive optics may help detect problems earlier.

Objectives:

- To study if adaptive optics can help find better ways to diagnose, treat, and manage retinal diseases.

Eligibility:

  • People over age 12 with an eye disease.
  • Healthy volunteers over age 12.

Design:

  • Participants will be screened with medical history and eye exams. These may include dilating pupils and taking pictures of the eyes.
  • Participants will have 1 or more study visits. They will have:
  • Medical and eye history.
  • Questions about their medications.
  • Eye exam including pupil dilation.
  • Adaptive optics imaging. After dilation, participants sit still while looking into an adaptive optics instrument. They look at specific places and images are taken of their retina.
  • They may also have:
  • More images.
  • Perimetry. Participants look into a lens and press a button when they see a light.
  • Color vision tests.
  • Electroretinogram. Participants will get numbing eye drops and special contact lenses. A small metal electrode will be put on their forehead. They will look at flashing lights and try not to blink.
Read the detailed description

Objective: The objective of this protocol is to collect and assess adaptive optics (AO) retinal images of normal and diseased eyes.

Study Population: Three hundred and fifty (350) participants with eye diseases and 250 normal volunteers will be enrolled.

Design: This is an observational protocol which will enroll 350 participants with various eye diseases and 250 age-matched healthy volunteers over five years. In general, participants will undergo a complete ophthalmic examination including assessments of visual acuity, intraocular pressure, and a dilated ocular examination. Imaging will be performed using adaptive optics instruments deployed in the NEI Eye Clinic.

Outcome Measures: The primary outcome for this protocol is qualitative and quantitative assessment of the AO images with comparisons of normal and diseased states.

02

Conditions studied

  • Eye Diseases
  • Healthy Volunteers

Browse trials for

Keywords

  • Eye Disease
  • Natural History
03

In context

Eye Diseases

389 studies on the registry are indexed under Eye Diseases; 62 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 180 across 109 observational studies indexed under Eye Diseases.

Browse Eye Diseases studies →

Lead sponsor

National Eye Institute (NEI) is the lead sponsor of 272 studies on the registry; 17 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 8 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

500 participants with eye diseases and 500 healthy volunteers will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants will be eligible if they:

  • Are 12 years of age or older.
  • Have the ability to cooperate with an eye exam and adaptive optics imaging.
  • Have the ability to understand and sign an or have a parent/legal guardian to do so if they are minor children.
  • Have an eye disease or are a healthy volunteer with a normal eye exam (no visually-significant eye findings on examination).

Exclusion criteria

EXCLUSION CRITERIA:

Participants will not be eligible if:

-They have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity).

EXCLUSION CRITERIA FOR FLUORESCEIN AND/OR INDOCYANINE GREEN IMAGING

Partaicipants are not eligible for fluorescein and/or indocyanine green imaging if they:

  • Are under 18 years of age.
  • For participants who will undergo fluorescein imaging have a history of adverse reaction to fluorescein.
  • For participants who will undergo indocyanine green imaging have a history of adverse reaction to indocyanine green dye, know or suspected allergies to iodine or shellfish.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
1,000 participants (estimated)

Groups and cohorts

  • Affected participants

    Participants with ocular conditions

  • Healthy Volunteers

    Healthy volunteers

06

What researchers measure

Primary outcomes

  1. Qualitative and quantitative assessment of AO images

    Qualitative and quantitative assessment of AO images with comparison of normal and diseased states.

    Time frame: ongoing

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Publications

  • Hendrickson A, Drucker D. The development of parafoveal and mid-peripheral human retina. Behav Brain Res. 1992 Jul 31;49(1):21-31. doi: 10.1016/s0166-4328(05)80191-3. PubMed 1388798 ↗
  • Wing GL, Blanchard GC, Weiter JJ. The topography and age relationship of lipofuscin concentration in the retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1978 Jul;17(7):601-7. PubMed 669891 ↗
  • Fotedar R, Wang JJ, Burlutsky G, Morgan IG, Rose K, Wong TY, Mitchell P. Distribution of axial length and ocular biometry measured using partial coherence laser interferometry (IOL Master) in an older white population. Ophthalmology. 2010 Mar;117(3):417-23. doi: 10.1016/j.ophtha.2009.07.028. Epub 2010 Jan 19. PubMed 20031227 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2015 (actual). Primary completion is estimated for Mar 2028, 157 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2014
First posted
Dec 16, 2014
StartActual
Feb 20, 2015
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02317328
Responsible party
Sponsor
First posted
Dec 16, 2014
Start date
Feb 20, 2015
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Daniel W Claus, R.N.
Contact
daniel.claus@nih.gov
(301) 451-1621
Johnny C Tam, Ph.D.
Contact
johnny.tam@nih.gov
(301) 435-7821
Johnny C Tam, Ph.D.
principal investigator · National Eye Institute (NEI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion